Breast cancer is not one single disease. Doctors sort it into types by asking three questions: where the cells started (in the milk ducts or in the lobules, the glands that make milk), whether the cells have grown beyond that starting point or stayed inside it, and what the laboratory tests show about the cells themselves. This guide compares the main types side by side in plain language, so the words in a diagnosis feel easier to take in.
Key Takeaways
- A breast cancer “type” names where the cancer started and how the cells look and behave under the microscope.
- The first split is in situ versus invasive: in situ means the cells have stayed where they started; invasive means they have grown into nearby breast tissue.
- Receptor results — ER, PR, and HER2 — act as a second label on top of the type, and they help the care team plan next steps.
- Type is not the same as stage or grade. Stage describes how far cancer has spread; grade describes how different the cells look from normal cells.
- Every person’s exact combination is personal. Your pathology report and your own care team are the source for what your type means for you.
What the Word “Type” Actually Means
After a biopsy — a test in which a small sample of tissue is removed and examined — a pathologist studies the cells under a microscope. A pathologist is a doctor who specializes in identifying diseases by looking at tissue and cells. The name of your breast cancer type comes from that examination, and it appears on your pathology report, the written record of what the laboratory found.
The type is built from a few sorting questions. Where did the cells start: in a duct or in a lobule? Have the cells stayed inside that structure, or have they grown through its wall into the tissue around it? And what did the extra laboratory tests show about the cells — in particular, tests for receptors, which are explained below. A full diagnosis line can look long, combining all of these answers at once, such as an invasive cancer that started in a duct and tested positive for hormone receptors but negative for HER2. Each part of that line carries its own meaning, and the sections below take them one at a time.
It can help to know that “type” works like a family name. It groups your cancer with others that share the same starting place and pattern of growth, which gives your care team a shared, precise language for talking about it. Two people can share a type name and still have quite different situations, because the type is only one part of the full picture.
The First Split: In Situ vs Invasive
The Latin words in situ mean “in its original place.” An in situ breast cancer is one in which the unusual cells are still contained inside the duct or lobule where they began. They have not grown through the wall of that structure into the surrounding breast tissue. Invasive breast cancer means the cells have grown beyond that wall into nearby tissue. From there, cells can potentially reach lymph nodes — small glands that are part of the immune system — or other parts of the body, which is why the distinction matters so much. Our separate guide explains in situ vs invasive breast cancer in more depth.
Ductal carcinoma in situ (DCIS)
Ductal carcinoma in situ, usually shortened to DCIS, is the in situ form that starts in a milk duct. The cells inside the duct have changed in ways that look like cancer under the microscope, but they have not spread beyond the duct. DCIS is sometimes called stage 0. It is often found by a mammogram before it can be felt. Because some DCIS may become invasive over time and some may not, doctors discuss treatment and follow-up carefully for each person rather than using one rule for everyone.
Lobular carcinoma in situ (LCIS)
Lobular carcinoma in situ, or LCIS, starts in the lobules. Despite the similar name, LCIS is usually described differently from DCIS: many doctors explain it less as a cancer itself and more as a sign that the risk of developing breast cancer later — in either breast — is higher than average. LCIS is often found by chance when a biopsy is done for another reason. The wording can be confusing, so our guide to DCIS vs LCIS walks through how these two findings differ.
A note on microinvasion
Sometimes a report describes DCIS with microinvasion. This means the laboratory found one or more extremely small spots where cells have just begun to grow beyond the duct. It sits at the border between in situ and invasive, and your care team can explain what it means in the context of your whole report.
Where It Starts: Ductal vs Lobular
Most breast cancers begin in one of two places. The ducts are the small tubes that carry milk toward the nipple. The lobules are the glands where milk is made. Cancers named “ductal” started in a duct; cancers named “lobular” started in a lobule. The word “carcinoma” simply means a cancer that begins in the lining cells of an organ or structure, which is the group nearly all breast cancers belong to.
Invasive ductal carcinoma (IDC)
Invasive ductal carcinoma is the most common invasive type. It starts in a milk duct and grows into the surrounding breast tissue. Because it is common, it is sometimes listed on reports with a longer name, “invasive carcinoma of no special type,” which means the cells do not show one of the special patterns described later in this guide. A lump that can be felt is a common way IDC is noticed, though it is also found on screening images.
Invasive lobular carcinoma (ILC)
Invasive lobular carcinoma starts in the lobules. Its cells tend to grow in single-file lines rather than in a firm ball, and they often lack a protein that normally helps cells stick together. Because of that growth pattern, ILC can be harder to feel as a distinct lump and sometimes harder to see on a mammogram; it may show up as an area of thickening instead. The ductal-versus-lobular distinction is about the starting point and growth pattern, and both types are then further described by their receptor results.
The Major Types, Side by Side
The table below places the major types next to each other using the sorting ideas from this guide: where each starts, whether it is in situ or invasive, and how receptor results fit in. It is a comparison of definitions, not of outlook — your care team can explain what these labels mean in your own case.
| Type | Where it starts | In situ or invasive? | Receptor results, in plain words |
|---|---|---|---|
| DCIS | Inside a milk duct | In situ — contained in the duct | Hormone receptors are often tested; HER2 is checked less often at this stage |
| LCIS | Inside the lobules | In situ — contained in the lobule; usually described as a risk marker rather than a cancer | Often hormone-receptor-positive; testing helps guide follow-up discussions |
| Invasive ductal carcinoma (IDC) | A milk duct, then grows outward | Invasive — grown into nearby tissue | Any pattern is possible; ER, PR, and HER2 are all tested |
| Invasive lobular carcinoma (ILC) | The lobules, then grows outward | Invasive — grown into nearby tissue, often in single-file lines | Often hormone-receptor-positive and HER2-negative, but every result is individual |
| Inflammatory breast cancer | Breast tissue and the tiny lymph channels in the skin | Invasive — defined by how it shows up in the skin | Any pattern is possible; all three receptors are tested |
| Paget’s disease of the breast | The skin of the nipple, usually with a cancer inside the breast | The underlying cancer may be in situ or invasive | Often HER2-positive; the underlying cancer is tested as usual |
| Metastatic breast cancer | Any breast starting point; cancer found in distant parts of the body | Describes spread, not a separate cell type | Any pattern is possible; receptors may be tested again on the new site |
Reading across a row shows how the labels combine. Reading down the receptor column shows why two people with the same type name can still receive different plans: the receptor results differ, and so does the rest of each person’s picture.
Receptor Status: A Second Label on Every Type
Receptors are proteins that sit on or inside cells and act like docking stations. When the right substance locks onto a receptor, it can send the cell a signal to grow. Laboratories test breast cancer cells for three receptors, and the results — positive (the receptor was found) or negative (it was not) — are added to the type name.
ER and PR: the hormone receptors
ER stands for estrogen receptor and PR for progesterone receptor. If a cancer is ER-positive or PR-positive, it is called hormone-receptor-positive, meaning hormones may be helping it grow. Treatments exist that work by blocking that signal or lowering hormone levels, which is why this result is so useful to the care team. Our guide to hormone-receptor-positive breast cancer explains this group in more detail.
HER2
HER2 is a protein that helps control how cells grow and divide. Some cancers make far too much of it, and those are called HER2-positive. Medicines have been designed to target HER2 directly, so this result also shapes planning. You can read more in our guide to HER2-positive breast cancer. Newer reports sometimes use the wording “HER2-low” when a small amount of HER2 is found; if you see that term, it is worth asking your team what it means in your case.
Triple-negative and triple-positive
When all three tests come back negative — no estrogen receptor, no progesterone receptor, and no extra HER2 — the cancer is called triple-negative. The name describes what was not found: medicines aimed at those three targets are not part of the picture, so the care team discusses other approaches. Our explainer on triple-negative breast cancer goes further. The opposite pattern, in which all three are positive, is called triple-positive. For a direct comparison of the two ideas, see triple-negative vs HER2-positive breast cancer.
Receptor status is best thought of as a set of switches. The type tells you where the cancer started and how it is growing; the switches add information about what may be driving that growth. A single tumor can also show more than one pattern in different areas, which is one reason reports sometimes sound complicated.
Less Common and Rare Types
Beyond the common types, pathologists recognize a set of less common patterns. Many are named for how the cells look under the microscope. Tubular, mucinous (also called colloid), medullary, and papillary cancers are special patterns of invasive cancer, each with its own typical appearance. Cribriform and micropapillary are other patterns you may see named on a report. Having a less common pattern does not automatically mean a better or worse situation — it is one more detail your care team weighs alongside stage, grade, and receptor results.
A few uncommon types deserve a mention by name because they behave or appear in distinctive ways. Inflammatory breast cancer is an invasive cancer that shows itself mainly through changes in the breast skin — redness, swelling, and warmth, sometimes with a dimpled look — because cancer cells are blocking tiny lymph channels in the skin. It may not form a lump at all, which is why new, persistent skin changes are worth having checked promptly. Paget’s disease of the breast affects the skin of the nipple and the darker circle around it (the areola), causing a scaly or crusted patch that can be mistaken for eczema; there is usually a DCIS or invasive cancer inside the breast as well.
Other rare findings start in different breast tissues rather than in ducts or lobules. Phyllodes tumors grow in the breast’s supporting tissue, and most of them are not cancer at all, though some are borderline or malignant (cancerous) and are monitored carefully. Angiosarcoma starts in blood vessels, metaplastic cancer contains a mixture of cell types, and secretory and adenoid cystic carcinomas are further uncommon patterns. If your report names a rare type, it is reasonable to ask your team how much experience they have with it and whether a second opinion at a center that sees rare types could add information — a question, never a verdict on your current care.
When Cancer Has Spread, and Breast Cancer in Men
Metastatic breast cancer is breast cancer that has spread to parts of the body far from the breast, such as the bones, liver, lungs, or brain. It is also called stage 4 or advanced breast cancer. “Metastatic” describes where the cancer is, not a separate type of cell: a metastatic cancer is still described by its original type and receptor results, because it is breast cancer wherever it is found. Cancer that was metastatic at the very first diagnosis is sometimes called “de novo” metastatic, a phrase that simply means “from the beginning.”
Breast cancer in men. Men have a small amount of breast tissue, and breast cancer can develop there too, though it is uncommon. The types mirror those in women — most often invasive ductal carcinoma, and DCIS occurs as well — and hormone-receptor-positive results are common. Because it is unexpected, it is sometimes found later; any new lump or nipple change in a man is worth having a doctor look at, without embarrassment.
Type Is Not the Whole Picture: Stage and Grade
Three words that sound alike — type, stage, and grade — answer three different questions. The type answers: where did it start, and how is it growing? The stage answers: how far has it spread? Stages run from 0 (in situ) through 4 (spread to distant parts of the body), and they take in the tumor’s size and whether lymph nodes are involved; our overview of breast cancer stages 0 to 4 explains each one. The grade answers: how do the cells look? A pathologist grades cells from 1 to 3 by how different they look from normal cells and how quickly they appear to be growing — grade 1 cells look closest to normal, and grade 3 cells look the most changed.
Reports may also mention a growth-rate marker called Ki-67, size measurements, whether the edges of removed tissue (the margins) are clear of cancer, and whether cancer was found in lymph nodes or in tiny vessels near the tumor. None of these details replaces the others. Your care team reads them together, along with your overall health and your own preferences, when discussing next steps.
Reading the Words in Your Pathology Report
A pathology report often reads like a list of unfamiliar terms, but most of those terms belong to the sorting system in this guide. The diagnosis line usually states the type first, then the grade, then the receptor results. Later sections may describe the tumor’s size, the lymph nodes examined, the margins, and any in situ cancer found alongside an invasive one — mixed findings are common and do not mean the report contradicts itself.
A practical approach is to read the report once for the type name, then again slowly with a pen, circling anything you do not recognize and writing your questions in the margin. Bring the marked-up copy to your next appointment. Our walkthrough of understanding your breast cancer pathology report goes through a report section by section, and it pairs well with the questions list below.
A Note About Numbers You May Go Looking For
Many readers understandably want figures — how common a type is, or what outcomes look like for people with a similar diagnosis. Numbers like these change as treatments improve and as new research is published, and small differences in how they are counted can make one source look very different from another. For that reason, this guide compares types by their definitions rather than by statistics. If you want current figures for a specific type, current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov), and your own care team can explain how any figure does — and does not — apply to your situation.
Questions to Ask Your Doctor
You do not need to memorize the classification system. You only need your own answers, and these questions can help you get them in plain words:
- What is the exact name of my type of breast cancer? Could you write it down for me?
- Is it in situ or invasive, and how do you know?
- What were my ER, PR, and HER2 results, and what do they mean for me?
- What are the stage and the grade? How are they different from the type?
- Were lymph nodes or margins mentioned in my report? What did they show?
- Are there parts of my report you would explain differently, or anything still being tested?
- Would a second opinion be helpful in my case, and how would I arrange one?
- Where can I read more about my type from a source you trust?
Frequently Asked Questions
Is DCIS considered breast cancer?
DCIS has the word “carcinoma” in its name because the cells show cancer-like changes under the microscope, but by definition those cells have not spread beyond the milk duct. It is often called stage 0. Doctors still take it seriously and discuss treatment or close follow-up, because in some people DCIS can become invasive over time. Whether and how to treat it depends on the details of your own report, so it is a conversation to have with your care team.
Can a person have more than one type or pattern at once?
Yes. A single breast can hold an invasive cancer alongside DCIS, a tumor can show a mixture of patterns, and the two breasts can have completely separate findings with different names. Receptor results can also vary between areas of one tumor. This is common enough that reports often list several findings together; your team reads them as one combined picture.
Does the type decide the treatment all by itself?
No. The type is one input among several. Your care team also weighs the receptor results, the stage, the grade, the tumor’s size, whether lymph nodes are involved, your overall health, and your own priorities. That is why two people with the same type name can be offered different plans, and why this guide describes types without recommending any particular treatment.
What does triple-negative mean for treatment, in general terms?
It means the three targets the laboratory tested — estrogen receptor, progesterone receptor, and HER2 — were not found, so medicines designed to aim at those targets are not part of the plan. It does not mean there are no treatments; other approaches exist and are a central part of the discussion with your care team. The details belong to that conversation, because they depend on the stage and the rest of your report.
Can receptor results change if the cancer comes back or spreads?
They can. A cancer that returns or spreads sometimes tests differently from the original tumor, which is one reason doctors may suggest a new biopsy of the new site. A changed result is not a mistake in the earlier test; it is new information, and it can affect the options your team discusses with you.
What should I do if my report uses words I don’t recognize?
Start by writing the words down and bringing them to your next appointment — explaining the report is part of your team’s job, and no question about it is too small. You can also ask for the report to be summarized in plain language, ask a nurse navigator or educator to walk through it with you, and read guides to the specific terms before the visit so the conversation feels less rushed.
Related Articles
- Inflammatory Breast Cancer: Signs and Treatment — how this uncommon invasive type shows up in the skin, and why it is checked promptly.
- Paget’s Disease of the Breast Explained — the nipple-skin condition that usually comes with a cancer inside the breast.
- Metastatic Breast Cancer Explained — what it means when breast cancer is found in distant parts of the body.
- Male Breast Cancer: Signs, Risks, and Treatment — the types men can develop and the signs worth having checked.
- DCIS vs Invasive Ductal Carcinoma — a closer look at what changes when cancer is no longer in situ.
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.